Skip to main content
. Author manuscript; available in PMC: 2013 Jan 30.
Published in final edited form as: J Control Release. 2011 Aug 17;157(2):287–296. doi: 10.1016/j.jconrel.2011.08.015

Figure 5. Immunohistographs of MDA-MB-468 tumors after treatment with EGF-GemC18-NPs or OVA-GemC18-NPs.

Figure 5

(A). Tumor tissues were staining with antibodies against BrdU, CD31, or caspase 3 (Cas 3). Scale bars = 100 μm.

(B). The % of BrdU positive cells.

(C). The % of caspase 3 positive cells.

(D). Tumor tissues after anti-EGFR antibody staining (green) and DAPI staining (blue).